Targeted multi-epitope dosage forms for induction of an immune response to antigens
AssigneeSelecta Biosciences, Inc.
InventorsCHRISTOPHER FRASER, Grayson B. Lipford, David H. Altreuter
Life of this patent
Estimating the term…
Abstract
Provided herein are compositions and methods related to MHC II binding peptides. In some embodiments, the peptides are obtained or derived from a common source. In other embodiment, the peptides are obtained or derived from an infectious agent to which a subject has been repeatedly exposed.
Claims45
A dosage form comprising:
- (i) an antigen;
- (ii) a composition comprising A-x-B;
- and
- (iii) a pharmaceutically acceptable excipient;
- wherein x may comprise a bond, no bond, or a linking group, or
- wherein x may comprise a linker or no linker, wherein the linker, optionally, comprises
- an amide linker, a disulfide linker, a sulfide linker, a 1,4-disubstituted 1,2,3-triazole linker, a thiol ester linker, a hydrazide linker, an imine linker, a thiourea linker, an amidine linker, or an amine linker, or
- a peptide sequence, a lysosome protease cleavage site, a biodegradable polymer, a substituted or unsubstituted alkane, alkene, aromatic or heterocyclic linker, a pH sensitive polymer, heterobifunctional linker or an oligomeric glycol spacer;
- wherein A comprises a first MHC II binding peptide, and the first MHC II binding peptide comprising a peptide having at least 70% identity to a natural HLA-DP binding peptide, a peptide having at least 70% identity to a natural HLA-DQ binding peptide, or a peptide having at least 70% identity to a natural HLA-DR binding peptide;
- wherein B comprises a second MHC II binding peptide, and the second MHC II binding peptide comprising a peptide having at least 70% identity to a natural HLA-DP binding peptide, a peptide having at least 70% identity to a natural HLA-DQ binding peptide, or a peptide having at least 70% identity to a natural HLA-DR binding peptide;
- wherein A and B do not have 100% identity to one another;
- and
- wherein the antigen and A and/or B are obtained or derived from a common source,
- and/or the first MHC II binding peptide and/or the second MHC II binding peptide comprise a peptide obtained or derived from an infectious agent to which a subject has been repeatedly exposed.
-3. (canceled)
(canceled)
-18. (canceled)
-21. (canceled)
-24. (canceled)
-29. (canceled)
-36. (canceled)
(canceled)
-42. (canceled)
(canceled)
-51. (canceled)
-54. (canceled)
-82. (canceled)
(canceled)
-91. (canceled)
-97. (canceled)
A dosage form comprising polypeptides, or nucleic acids that encode the polypeptides, and/or antigens;
- wherein the antigens and/or at least a portion of the polypeptides are obtained or derived from a common source and/or obtained or derived from an infectious agent to which a subject has been repeatedly exposed;
- and
- the sequences of the polypeptides comprise amino acid sequences that have at least 75% identity to any one of the amino acid sequences set forth as SEQ ID NOs:
- 1-46, 71-98, 100-115 and 119.
-101. (canceled)
A dosage form or composition comprising polypeptides, or nucleic acids that encode the polypeptides, wherein the polypeptides comprise amino acid sequences set forth as any one of SEQ ID NOs:
- 1-46, 71-98, 100-115 and 119.
-109. (canceled)
-115. (canceled)
-128. (canceled)
Dependencies are inferred from the claim text.